comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 21:34:08 - browse：2586

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Leukemia patients are helped by Syndax's new type of therapy

knowledge

WSS

In diabetes hearing, Sanders takes on a new foe: food makers

The woman behind the Dana Farber

Maker of FluMist seeks to allow at

WHO may add ‘noma' to its list of neglected tropical diseases

Teach medical students about patients with intellectual disabilities

Meta's Zuckerberg and Chan on track to put $50 billion into science

explore

comprehensive

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

AI models in health care face new federal disclosure requirements

Psychedelics group wrestles with new pharma identity

The FDA weighs the risks of candy

At least 13 dead in Texas as scorching temps continue

Meta's Zuckerberg and Chan on track to put $50 billion into science

State Dept. review finds Biden bears some blame for Afghanistan failures

AI models in health care face new federal disclosure requirements

Tori Bowie and the unacceptable rates of Black maternal death

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

explore

Radiology is caught between AI's potential and concern for patients

The FDA weighs the risks of candy

Telehealth options flood the market as retailers push virtual care

Chemotherapy shortages won’t get better under Biden’s latest plan

In diabetes hearing, Sanders takes on a new foe: food makers

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Wikipedia

leisure time

knowledge

focus